Evaluating Multisite rCBV Consistency from DSC-MRI Imaging Protocols and Postprocessing Software Across the NCI Quantitative Imaging Network Sites Using a Digital Reference Object (DRO)

Laura C. Bell, Natenael Semmineh, Hongyu An, Cihat Eldeniz, Richard Wahl, Kathleen M. Schmainda, Melissa A. Prah, Bradley J. Erickson, Panagiotis Korfiatis, Chengyue Wu, Anna G. Sorace, Thomas E. Yankeelov, Neal Rutledge, Thomas L. Chenevert, Dariya Malyarenko, Yichu Liu, Andrew Brenner, Leland S. Hu, Yuxiang Zhou, Jerrold L. BoxermanYi Fen Yen, Jayashree Kalpathy-Cramer, Andrew L. Beers, Mark Muzi, Ananth J. Madhuranthakam, Marco Pinho, Brian Johnson, C. Chad Quarles

Research output: Contribution to journalArticle

Abstract

Relative cerebral blood volume (rCBV) cannot be used as a response metric in clinical trials, in part, because of variations in biomarker consistency and associated interpretation across sites, stemming from differences in image acquisition and postprocessing methods (PMs). This study leveraged a dynamic susceptibility contrast magnetic resonance imaging digital reference object to characterize rCBV consistency across 12 sites participating in the Quantitative Imaging Network (QIN), specifically focusing on differences in site-specific imaging protocols (IPs; n = 17), and PMs (n = 19) and differences due to site-specific IPs and PMs (n = 25). Thus, high agreement across sites occurs when 1 managing center processes rCBV despite slight variations in the IP. This result is most likely supported by current initiatives to standardize IPs. However, marked intersite disagreement was observed when site-specific software was applied for rCBV measurements. This study's results have important implications for comparing rCBV values across sites and trials, where variability in PMs could confound the comparison of therapeutic effectiveness and/or any attempts to establish thresholds for categorical response to therapy. To overcome these challenges and ensure the successful use of rCBV as a clinical trial biomarker, we recommend the establishment of qualifying and validating site- and trial-specific criteria for scanners and acquisition methods (eg, using a validated phantom) and the software tools used for dynamic susceptibility contrast magnetic resonance imaging analysis (eg, using a digital reference object where the ground truth is known).

Original languageEnglish (US)
Pages (from-to)110-117
Number of pages8
JournalTomography (Ann Arbor, Mich.)
Volume5
Issue number1
DOIs
StatePublished - Mar 1 2019

    Fingerprint

Keywords

  • DSC-MRI
  • multisite consistency
  • relative cerebral blood volume
  • reproducibility
  • standardization

Cite this

Bell, L. C., Semmineh, N., An, H., Eldeniz, C., Wahl, R., Schmainda, K. M., Prah, M. A., Erickson, B. J., Korfiatis, P., Wu, C., Sorace, A. G., Yankeelov, T. E., Rutledge, N., Chenevert, T. L., Malyarenko, D., Liu, Y., Brenner, A., Hu, L. S., Zhou, Y., ... Quarles, C. C. (2019). Evaluating Multisite rCBV Consistency from DSC-MRI Imaging Protocols and Postprocessing Software Across the NCI Quantitative Imaging Network Sites Using a Digital Reference Object (DRO). Tomography (Ann Arbor, Mich.), 5(1), 110-117. https://doi.org/10.18383/j.tom.2018.00041